Survival after secondary cytoreduction for recurrent ovarian cancer: Which are the prognostic factors?

Journal of Surgical Oncology

Volumn 102, Issue 6, 2010, Pages 671-675

  Biliatis, Ioannis ^a   Haidopoulos, Dimitrios ^a   Rodolakis, Alexandros ^a   Vlachos, Georgios ^a   Protopapas, Athanasios ^a   Thomakos, Nikolaos ^a   Sergentanis, Theodoros ^a   Akrivos, Nikolaos ^a   Antsaklis, Aris ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

clear cell adenocarcinoma; complete cytoreduction; FIGO stage

Indexed keywords

PACLITAXEL; PLATINUM DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; COLOSTOMY; CYSTECTOMY; CYTOREDUCTIVE SURGERY; DISEASE FREE INTERVAL; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPHADENECTOMY; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PERITONEAL LYMPHADENECTOMY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SECONDARY CYTOREDUCTION; SPLENECTOMY; SURVIVAL TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROGNOSIS; RECURRENCE; REOPERATION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 78349280245     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21686     Document Type: Article

References (30)

1. Bristow RE, Tomacruz RS, Armstrong DK, et al.: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 2002; 20: 1248-1259.
2. Ozols RF, Bundy BN, Greer BE, et al.: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2003; 21: 194-200.
3. Griffiths CT:, Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975; 42: 101-104.
4. Gaducci A, Iacconi P, Cosio S, et al.: Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecol Oncol 2000; 79: 344-349.
5. Ozols RF:, Recurrent ovarian cancer: Evidence-based treatment. J Clin Oncol 2002; 20: 1161-1163. (Pubitemid 34177419)
6. Janicke F, Holscher M, Kuhn W, et al.: Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer 1992; 70: 129-136.
7. Vaccarello L, Rubin SC, Vlamis V, et al.: Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response. Gynecol Oncol 1995; 57: 61-65.
8. Eisenkop SM, Friedman RL, Spirtos NM:, The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 2000; 88: 144-153.
9. Onda T, Yoshikawa H, Yasugi T, et al.: Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: Proposal for patients selection. Br J Cancer 2005; 92: 1026-1032.
10. Morris M, Gershenson DM, Wharton JT:, Secondary cytoreductive surgery in epithelial ovarian cancer: Non-responders to first-line therapy. Gynecol Oncol 1989; 33: 1-5.
11. Michel G, Zarca D, Castaigne D, et al.: Secondary cytoreductive surgery in ovarian cancer. Eur J Surg Oncol 1989; 61: 2571-2577.
12. Scarabelli C, Gallo A, Carbone A:, Secondary cytoreductive surgery for patients with recurrent ovarian carcinoma. Gynecol Oncol 2001; 83: 504-512.
13. Zang RY, Li ZT, Tang J, et al.: Secondary cytoreductive surgery for patients with relapsed ovarian carcinoma: Who benefits ? Cancer 2004; 100: 1152-1161. (Pubitemid 38325942)
14. Gronlud B, Lundvall L, Christensen IJ, et al.: Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum. Eur J Surg Oncol 2005; 31: 67-73.
15. Ayhan A, Gultekin M, Taskiran C, et al.: The role of secondary cytoreduction in the treatment of ovarian cancer: Hacettepe University experience. Am J Obstet Gynecol 2006; 194: 49-56.
16. Chi DS, McCaughty K, Diaz JP, et al.: Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 2006; 106: 1933-1939.
17. Harter P, du Bois A, Hahmann M, et al.: Surgery in recurrent ovarian cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 2006; 13: 1702-1710.
18. Salani R, Santillan A, Zahurak ML, et al.: Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer. Cancer 2007; 109: 685-691.
19. Benedetti Panici P, DeVico A, Bellati F, et al.: Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. Ann Surg Oncol 2007; 14: 1136-1142.
20. Oksefjell H, Sandstad B, Trope C:, The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer. Ann Oncol 2009; 20: 286-293.
21. Munkarah AR, Coleman RL:, Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol Oncol 2004; 95: 273-280.
22. Therasse P, Arbuck SG, Eisenhauer EA, et al.: New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
23. Vergote I, Rustin GJS, Eisenhauer EA, et al.: Re: New guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]: Gynecologic Cancer Intergroup. J Natl Cancer Inst 2000; 92: 1534-1535.
24. Berek JS:, Ovarian cancer. In:, Hacker NF, Moore JG, Gambone JC, editors. Essentials of obstetrics and gynecology, 4th edition. Philadelphia, PA: Elsevier Saunders; 2004. pp 459-468.
25. Goff BA, Sainz de la cuesta R, Muntz HG, et al.: Clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996; 60: 312-317.
26. Sugiyama T, Kamura T, Kigawa J, et al.: Clinical characteristics of clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000; 88: 2584-2589.
27. Timmers PJ, Zwinderman AH, Teodorovic I, et al.: Clear cell carcinoma compared to serous carcinoma in early ovarian cancer: Same prognosis in a large randomized trial. Int J Gynecol Cancer 2009; 19: 88-93.
28. Bristow RE, Puri I, Chi DS:, Cytoreductive surgery for recurrent ovarian cancer: A meta-analysis. Gynecol Oncol 2009; 112: 265-274.
29. Morris M, Gershenson DM, Wharton JT, et al.: Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol 1989; 34: 334-338.
30. Munkarah A, Levenback C, Wolf JK, et al.: Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer. Gynecol Oncol 2001; 81: 237-241.